Abstract 93P
Background
Endometrial carcinomas (EC) are the most common gynecological cancer in the developed world. The original histopathology-based classification has been supplemented in the recent years by a molecular classification, based on the analysis of POLE mutation, microsatellite instability (MSI) and copy number variation. These markers have been used to develop prognostic risk groups with specific treatment options. Hence, the molecular stratification has been recommended internationally by different organizations and associations (e.g., ESMO, ESGO), allowing individualized treatment stratifications. Historically, these markers have been analyzed by various methods such as immunohistochemistry (IHC), Sanger sequencing and PCR-based fragment analysis. But the lack of single streamlined workflow has hampered the widespread adoption.
Methods
We developed three assays for discrimination of EC into ultramutated (POLE), hypermutated (MSI) and copy number high (CN high) phenotypes. CN high tumors are stratified based on molecular level with two newly identified biomarkers. We pre-characterized a patient cohort compromising of 41 samples, using IHC (MLH1, MSH2, MSH6, PMS2 and the surrogate marker TP53). Using our proprietary molecular analysis platform MODAPLEX, that unifies PCR and capillary gel electrophoresis, we analyzed this cohort with the three assays with a 4-hour turn-around time. The concordance was determined by calculation of the sensitivity.
Results
The concordance analysis of our MODAPLEX assays revealed a sensitivity of 0.923 (95% CI [0.781, 1.066]) for MSI compared to the IHC results and 0.833 (95% CI [0.622, 1.044]) for CN high compared to p53-IHC, respectively. We verified 100% of the mutations identified with the MODAPLEX POLE/POLD1 assay.
Conclusions
Overall, this study demonstrates a multi-gene/multi-marker testing workflow with complete molecular stratification for EC into a single streamlined, time- and cost-effective run. This approach will allow timely access to molecular-guided therapy for individual patients by enabling same day results, with a relative ease of implementation and fully integrated data analysis.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Biotype GmbH, Dresden, Germany.
Funding
Biotype GmbH, Dresden, Germany.
Disclosure
S. Walz, C. Schanzenbach, A. Aich, R. Weißbach, R. Braun, A. Hennig, J. Schoebel, S. Hofmann: Financial Interests, Institutional, Full or part-time Employment: Biotype GmbH.
Resources from the same session
30P - Role of microRNA and CDKN2A/p16INK4a expression in the prognostication of oral squamous cell carcinoma
Presenter: Olha Burtyn
Session: Cocktail & Poster Display session
Resources:
Abstract
31P - Identification of proteins associated with mRNA processing and maturation by quantitative proteomic analysis in Indian cervical cancer patients
Presenter: Amrita Mukherjee
Session: Cocktail & Poster Display session
Resources:
Abstract
32P - Expression of STAT3 and hypoxia markers in repeatedly resected glioma patients
Presenter: Katerina Dvorakova
Session: Cocktail & Poster Display session
Resources:
Abstract
33P - Unraveling the mechanisms of cisplatin resistance in bladder organoid by single cell RNA sequencing
Presenter: Tingting Xie
Session: Cocktail & Poster Display session
Resources:
Abstract
34P - Functional diagnostics and ex-vivo screening of erlotinib and nintedanib in non-small cell lung carcinoma: Implications for multidrug resistance and personalized therapy
Presenter: Jelena Dinić
Session: Cocktail & Poster Display session
Resources:
Abstract
35P - Enhancing efficacy of the MEK inhibitor trametinib in KRAS-mutated colorectal cancer cells
Presenter: Lee Ellis
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Comparison of pelitinib, tepotinib or docetaxel efficacy according to the copy number or gene alteration status of EGFR, MET, HRAS, KRAS and NRAS genes
Presenter: Dae Young Zang
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - NET-mediated radio-resistance in early-stage non-small cell lung cancer
Presenter: Malcolm Ryan
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - The use of antibiotics or proton pump inhibitors and the response to intravesical Bacillus Calmette Guérin therapy in non-muscle-invasive bladder cancer
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - YAP1 promotes sorafenib resistance by activation of TGFβ signaling pathway
Presenter: Chit Lai Chee
Session: Cocktail & Poster Display session
Resources:
Abstract